Christine Lind, an ex-investment banker and currently strategic planner at Medivir AB, is to become the Swedish oncology company’s chief executive on 1 April. She will replace Niklas Prager, who has been acting CEO since 2014 and will continue as an advisor until early May.
Ms Lind is a US citizen with a bachelor’s degree in finance and information systems from New York University and a master’s degree in business administration from Columbia University. She worked for Merrill Lynch & Co for nine years, subsequently moving to LifeCell Corporation as head of business development.
Medivir announced the appointment on 9 February 2017.
Copyright 2017 Evernow Publishing Ltd